The Centers for Medicare & Medicaid Services just announced the next 15 brand-name medicines selected for Medicare’s drug price negotiation program, which mandates price reductions of at least 25%.
Nine-Point-Seven Percent CAGR Reflects Fundamental Industry Shift Toward Advanced LC-MS/MS and High-Resolution Platforms ...
3h
Top Pharmaceutical API Manufacturer Navigates Shifts in Global Drug Supply and Regulatory Landscape
According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...
The pharmaceutical industry operates under an uncompromising mandate: zero defects. Every tablet, capsule, vial, or syringe ...
VRC Medical Services, a specialty pharmaceutical distribution company supporting clinical research, announced recent ...
FY 2025 sales growth of 10.9% at CER1, or 8.1% as reported, driven by growth of the three therapeutic areas of Oncology (4.1%1), Rare Disease ...
The Health Ministry proposes draft amendments to remove provisional registration for ethics committees, aiming to streamline ...
Possible areas of co-operation between Belarus and a large Indian pharmaceutical company are being worked out during the visit of a ...
Researchers found that revenues from these negotiated drugs account for just 10% of the companies' total revenue and that these firms remain highly profitable despite price reductions for Medicare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results